Related references
Note: Only part of the references are listed.Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2016)
Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis
J. -F. Colombel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
Glen S. Hazlewood et al.
GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Brian Bressler et al.
GASTROENTEROLOGY (2015)
Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2015)
Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
Konstantinos Papamichael et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
Christopher Ma et al.
JOURNAL OF CROHNS & COLITIS (2014)
Comparative Efficacy of Biologic Therapy in Biologic-Naive Patients With Crohn Disease: A Systematic Review and Network Meta-analysis
Siddharth Singh et al.
MAYO CLINIC PROCEEDINGS (2014)
Time of infliximab therapy initiation and dose escalation in Crohn's disease
Mindy C. W. Lam et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses
Monia Marchetti et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
Effects of Discontinuing Anti-Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure
Zuzana Zelinkova et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Jonathan P. Terdiman et al.
GASTROENTEROLOGY (2013)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Direct medical cost of managing IBD patients: A Canadian population-based study
Charles N. Bernstein et al.
INFLAMMATORY BOWEL DISEASES (2012)
Implementing changes in clinical practice to improve the management of Crohn's disease
Remo Panaccione et al.
Journal of Crohns & Colitis (2012)
Intensification of infliximab therapy in Crohn's disease: Efficacy and safety
M. Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2012)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis
John Paul Leombruno et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab
G. Bouguen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Pal Miheller et al.
BMC GASTROENTEROLOGY (2009)
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort
Christopher W. Teshima et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
